Immunometabolism in systemic lupus erythematosus

Area of Science:

• Immunology
• Metabolic pathways
• Autoimmune diseases

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibodies against nucleoprotein complexes.
• Immune cell dysregulation, including B cells, T cells, dendritic cells, macrophages, and neutrophils, is central to SLE pathogenesis.
• Metabolic processes are critical for immune cell function and are implicated in autoimmune diseases.

Purpose of the Study:

• To review current knowledge on immune cell metabolic alterations in SLE.
• To discuss the role of these metabolic changes in SLE pathogenesis.
• To explore potential therapeutic strategies targeting immune cell metabolism in SLE.

Main Methods:

• Review of existing literature on immune cell metabolism in SLE and normal immune responses.
• Analysis of data from SLE patients and lupus-prone mouse models.
• Discussion of metabolic regulation in various immune cell types.

Main Results:

• Patients with SLE and lupus-prone mice exhibit activated CD4+ T cell metabolism.
• Metabolic inhibitors targeting activated CD4+ T cells show therapeutic potential in SLE.
• Metabolic requirements of B cells and myeloid cells in SLE are less understood.

Conclusions:

• Immune cell metabolic reprogramming is a key feature of SLE.
• Targeting T cell metabolism offers a promising therapeutic avenue for SLE.
• Further research is needed to elucidate the metabolic basis of B cell and myeloid cell dysfunction in SLE.